Tami Mark

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter

Filter by Year

Search Results

Untreated psychiatric and substance use disorders among caregivers with children reported to child protective services

Linked child welfare and Medicaid data in Kentucky and Florida highlights racial disparities in access to care

Association of Arizona's implementation of a behavioral health crisis response system with suicide hospitalizations

Improving research on racial disparities in access to medications to treat opioid use disorders

Findings from implementing a patient experience survey in a quality measurement system for substance abuse disorder treatment facilities in 6 states

The cost of opioid use disorder-related conditions in Medicare

The United States must improve its data infrastructure to ensure high-quality mental health care

It’s time for states to measure the effectiveness of their OUD treatment systems

Assessing assessments: Substance use disorder treatment providers' perceptions of intake assessments

Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder

Substance use disorders among Medicare beneficiaries: Prevalence, mental and physical comorbidities, and treatment barriers

Addiction treatment and telehealth: Review of efficacy and provider insights during the COVID-19 pandemic

Changes in Buprenorphine prescribing to Medicaid beneficiaries during the first year of the COVID-19 pandemic

Development, testing, and dissemination of a public-facing tool to help consumers find higher-quality addiction treatment

What's in an "ASAM-based Assessment?" Variations in assessment and level of care determination in systems required to use ASAM patient placement criteria

The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States

"The assessment really helps you with the first step in recovery": What do clients think substance use disorder treatment intake assessments should look like?

Is implementation of ASAM-based addiction treatment assessments associated with improved 30-day retention and substance use?

Changes in admissions to specialty addiction treatment facilities in California During the COVID-19 pandemic

Impact of the coronavirus pandemic on substance use disorder treatment: Findings from a survey of specialty providers in California